Keratoacanthoma: Rapid-Growing Skin Lesion – Diagnosis & Management

Keratoacanthoma (KA) is a common, rapidly growing, low-grade squamous cell carcinoma variant that often regresses spontaneously. It arises from hair follicle epithelium on sun-exposed skin.

Clinical Features

  • Onset: Rapid growth over 2–6 weeks to 1–3 cm dome-shaped nodule
  • Appearance: Symmetrical, flesh-colored to reddish, smooth surface with central keratin crater (horn plug)
  • Location: Face, ears, scalp, forearms, dorsum of hands
  • Demographics: Older adults (>60), fair skin, male predominance
  • Symptoms: Often asymptomatic; may be tender, pruritic, or bleed

Differential Diagnosis

  • Squamous cell carcinoma (SCC): Irregular borders, induration, fixation, slower growth, higher metastatic potential
  • Basal cell carcinoma: Pearly telangiectatic papule, rolled borders, ulceration
  • Seborrheic keratosis: Stuck-on, waxy, verrucous, no central crater
  • Wart (verruca vulgaris): Rough, hyperkeratotic, multiple, viral etiology

Diagnosis

Biopsy (shave or punch) is required to distinguish KA from well-differentiated SCC. Histology: cup-shaped architecture with central keratin mass, glassy eosinophilic keratinocytes, minimal atypia, pushing margins. Clinical diagnosis alone is insufficient.

Treatment Options

MethodIndicationCure RateNotes
Surgical excision (4–5 mm margins)Definitive treatment; all locations95–99%Gold standard; allows full histologic assessment
Mohs micrographic surgeryHigh-risk sites (face, ears), recurrent, ill-defined97–99%Tissue-sparing; real-time margin control
Curettage & electrodesiccation (C&E)Small, low-risk trunk/extremities90–95%Less cosmetic; no specimen for margins
Intralesional therapyNon-surgical candidates, multiple lesionsVariable5-FU, methotrexate, bleomycin; limited evidence
Radiation therapyElderly, non-surgical, large lesions90%+Fractionated; long-term carcinogenesis risk
ObservationClassic KA in very elderly/frail; patient declines treatmentSpontaneous regression in ~50% over 2–6 monthsRisk: progression to invasive SCC, scarring

Follow-Up

  • Skin exams every 6–12 months (increased risk of subsequent NMSC)
  • Sun protection: broad-spectrum SPF 30+, protective clothing, avoidance of peak UV
  • Consider nicotinamide 500 mg BID (ONTRAC trial: 23% reduction in new NMSC)

Keratoacanthoma behaves benignly in most cases, but definitive histologic diagnosis and treatment are standard of care to exclude invasive SCC and ensure optimal cosmetic outcome.

Tumors - Related Articles